

XYRATEX LTD  
Form 6-K  
January 06, 2005

[QuickLinks](#) -- Click here to rapidly navigate through this document

---

---

**U.S. SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER  
THE SECURITIES EXCHANGE ACT OF 1934**

January 6, 2005

---

**XYRATEX LTD**

(Registrant's name)

---

**Langstone Road  
Havant  
PO9 1SA**

(Address of Principal Executive Offices)

---

Indicate by check mark whether the registrant files annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

---

---

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

XYRATEX LTD

---

(Registrant)

By /s/ RICHARD PEARCE

---

Name: Richard Pearce  
Title: Chief Financial Officer

Date: January 6, 2005

---

**NEWS RELEASE**

For Immediate Release

**Xyratex Ltd Announces Results for the Fourth Quarter and Fiscal Year 2004**

Q4 Revenues \$116.7 million, up 17.4% Year over Year

Fiscal year 2004 Revenues \$459 million, up 37.5% Year over Year

**Havant, UK January 6, 2005** Xyratex Ltd (Nasdaq: XRTX), a leading provider of enterprise class data storage subsystems and network technology, today announced results for the fourth quarter and fiscal year ended November 30<sup>th</sup>, 2004. Revenues for the quarter were \$116.7 million, an increase of 17.4% compared to revenues of \$99.4 million for the same period last year and a 1.6% increase compared to \$114.9 million in the prior quarter.

For the fourth fiscal quarter, GAAP net income was \$8.2 million, or \$0.29 per diluted share. Non-GAAP net income from continuing operations increased 48.7% to \$5.4 million, or a diluted earnings per share of \$0.19, compared to non-GAAP net income of \$3.7 million in the same quarter a year ago. A reconciliation between net income on a GAAP basis and net income on a non-GAAP basis is provided in a table immediately following the "Consolidated Statements of Cash Flows", below.

Non-GAAP gross profit margin before equity compensation in the fourth quarter was 20.8%, compared to 22.3% in the same period last year and 22.7% in the prior quarter.

Revenues for fiscal year 2004 were \$459.0 million, an increase of 37.5%, compared to revenues of \$333.8 million for fiscal year 2003.

As a result of the IPO in 2004, Xyratex recorded a non-cash equity compensation expense of \$181.1 million for fiscal year 2004. This resulted in a GAAP net loss of \$135.2 million, or a loss per share of \$7.43.

Non-GAAP net income from continuing operations for fiscal year 2004 increased 51.8% to \$30.8 million, or a diluted earnings per share of \$1.18, compared to non-GAAP net income from continuing operations of \$20.3 million for fiscal 2003.

"Xyratex posted a very solid performance during the quarter with revenues growing over 17% year over year. Our fiscal year performance was outstanding and reflects the strength of our customers in a growing market and the strong industry trends that our technology supports," said Steve Barber, CEO of Xyratex. "Our strategy has produced solid results in both of our core business areas and across multiple segments. Our focus is on expanding our market share and the number of customers we provide technology solutions to. We plan to continue investing in our business to take full advantage of current and emerging market opportunities."

**Business Highlights**

We demonstrated the first enterprise class storage enclosure based on Serial Attached SCSI expander technology. We believe that the introduction of SAS technology to Storage Systems is an important step towards providing truly enterprise class, low cost storage solutions for our customers. The combination of robust enterprise SCSI protocol on top of a low cost SATA physical transport looks very attractive to us. Reducing the number of protocol decodes within any storage system is important in reducing cost and power and simplifies the overall integration effort.

We signed a contract with Maxtor Corporation to supply automated production equipment for high volume disk drive testing. The system is based on Xyratex's highly successful "single cell" technology, which offers disk drive manufacturers the capability of testing their products more efficiently than with conventional systems, uniquely providing a separately configurable and controllable environment for each individual drive to be tested.

---

## Edgar Filing: XYRATEX LTD - Form 6-K

We participated in a demonstration of the industry's first multi-vendor 4 Gb Fibre Channel SAN with our technology partners. We attached our 4Gb SBOD Storage Enclosure into a SAN which contained both 2Gb and 4Gb Fibre Channel devices. This is the third generation of our SBOD enclosure technology and we believe its robust system architecture will become increasingly more important as data rates continue to rise. Xyratex continues to support the evolution of the Fibre Channel roadmap and actively participates in these important early demonstrations. The 4Gb Fibre Channel technology will form the foundation of the next generation high performance storage enclosures in 2005.

### Business Outlook

The following statements are based on current expectations. These statements are forward-looking, and actual results may differ materially. These statements do not include the potential impact of any future acquisitions or divestitures.

Revenue in the first fiscal quarter of 2005 is projected to be in the range \$120 to \$127 million.

Fully diluted earnings per share is anticipated to be between \$0.14 and \$0.19 on a GAAP basis in the first quarter. On a non-GAAP basis fully diluted earnings per share is anticipated to be between \$0.17 and \$0.22. Non-GAAP earnings per share excludes non-cash equity compensation, amortization of intangible assets, certain other acquisition related charges and related taxation expense.

### Conference Call Information

**The Xyratex quarterly results conference call** will be broadcast live via the internet at <http://www.xyratex.com/investors> on Thursday, January 6, 2005 at 5:30 a.m. Pacific Time/8:30 a.m. Eastern Time. The press release will be posted to the company web site [www.xyratex.com](http://www.xyratex.com).

**A replay will be available through January 13, 2005** following the live call by dialing (866) 800-8652 in the United States and (617) 614-2705 outside the United States, replay code 44978138.

### Safe Harbor Statement

The foregoing information contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. These risks and other factors include those listed under "Risk Factors" and elsewhere in our Registration Statement on Form F-1 as filed with the Securities and Exchange Commission (File No. 333-116083). In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "intends," "plans," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

### About Xyratex

Xyratex is a leading provider of enterprise class data storage subsystems and network technology. The company designs and manufactures enabling technology that provides OEM and disk drive manufacturer customers with data storage products to support high-performance storage and data communication networks. Xyratex has over 20 years of experience in research and development relating to disk drives, storage systems and high-speed communication protocols.

---

## Edgar Filing: XYRATEX LTD - Form 6-K

Founded in 1994 in a management buy-out from IBM, and with its headquarters in the UK, Xyratex has an established global base with R&D and operational facilities in Europe, the United States and South East Asia.

---

Contacts:

**Xyratex Investor Relations**

Brad Driver  
Tel: +1 (408) 325-7260  
Email: [bdriver@us.xyratex.com](mailto:bdriver@us.xyratex.com)  
Website: [www.xyratex.com](http://www.xyratex.com)

**Xyratex Public Relations**

Curtis Chan  
CHAN & ASSOCIATES, INC.  
Tel: +1 (714) 447-4993  
Email: [cj\\_chan@chanandassoc.com](mailto:cj_chan@chanandassoc.com)

---

**XYRATEX LTD**  
**UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

|  | Three Months Ended   |                      | Year Ended           |                      |
|--|----------------------|----------------------|----------------------|----------------------|
|  | November 30,<br>2004 | November 30,<br>2003 | November 30,<br>2004 | November 30,<br>2003 |
| (US dollars in thousands, except per share amounts)              |                      |                      |                      |                      |
| Revenues   | \$ 116,701           | \$ 99,363            | \$ 459,014           | \$ 333,769           |
| Cost of revenues non cash equity compensation                    | 36                   | 690                  | 7,827                | 690                  |
| Cost of revenues other   | 92,451               | 77,242               | 356,558              | 260,020              |
| Total cost of revenues   | 92,487               | 77,932               | 364,385              | 260,710              |
| Gross profit   | 24,214               | 21,431               | 94,629               | 73,059               |
| Operating expenses:  |                      |                      |                      |                      |
| Research and development development arrangement                 |                      |                      | (6,000)              |                      |
| Research and development non cash equity compensation            | 83                   | 2,428                | 23,959               | 2,428                |
| Research and development other                                   | 10,597               | 10,529               | 37,429               | 29,797               |
| Total research and development                                   | 10,680               | 12,957               | 55,388               | 32,225               |
| Selling, general and administrative non cash equity compensation | 478                  | 54,143               | 136,363              | 54,143               |
| Selling, general and administrative other                        | 7,884                | 8,210                | 28,005               | 22,426               |
| Total selling, general and administrative                        | 8,362                | 62,353               | 164,368              | 76,569               |
| Amortization of intangible assets                                | 397                  |                      | 1,169                |                      |
| In process research and development                              | 852                  |                      | 852                  |                      |
| Other costs  | (201)                | 11,625               | 2,388                | 11,625               |
| Total operating expenses   | 20,090               | 86,935               | 224,165              | 120,419              |
| Operating income (loss)  | 4,124                | (65,504)             | (129,536)            | (47,360)             |
| Interest income (expense), net                                   | 147                  | (15)                 | 1,052                | (209)                |
| Income (loss) from continuing operations before income taxes     | 4,271                | (65,519)             | (128,484)            | (47,569)             |
| Benefit for income taxes(a)                                      | (3,937)              | (13,047)             | (6,239)              | (11,754)             |
| Net income (loss) from continuing operations                     | 8,208                | (52,472)             | (122,245)            | (35,815)             |
| Loss from discontinued operations (net of taxes of zero)         |                      | (19,940)             | (12,924)             | (20,194)             |
| Loss from sale of discontinued operations (net of taxes of zero) |                      |                      |                      | (185)                |
| Net income (loss)  | \$ 8,208             | \$ (72,412)          | \$ (135,169)         | \$ (56,194)          |
| Net earnings (loss) per share basic:                             |                      |                      |                      |                      |
| Net income (loss) from continuing operations                     | \$ 0.29              | \$ (5.61)            | \$ (6.72)            | \$ (9.60)            |
| Loss from discontinued operations, net of income tax             |                      | (2.13)               | (0.71)               | \$ (5.41)            |
| Loss from sale of discontinued operations, net of income tax     |                      |                      |                      | \$ (0.05)            |

Edgar Filing: XYRATEX LTD - Form 6-K

|   | Three Months Ended |           | Year Ended |            |
|---|--------------------|-----------|------------|------------|
|   |                    |           |            |            |
| Net earnings (loss) per share   | \$ 0.29            | \$ (7.74) | \$ (7.43)  | \$ (15.07) |
| Net earnings (loss) per share diluted:  |                    |           |            |            |
| Net income (loss) from continuing operations  | \$ 0.29            | \$ (5.61) | \$ (6.72)  | \$ (9.60)  |
| Loss from discontinued operations, net of income tax  |                    | (2.13)    | (0.71)     | (5.41)     |
| Loss from sale of discontinued operations, net of income tax  |                    |           |            | (0.05)     |
| Net earnings (loss) per share   | \$ 0.29            | \$ (7.74) | \$ (7.43)  | \$ (15.07) |
| Weighted average common shares, class B preferred ordinary shares and class B ordinary shares (in thousands), used in computing net earnings per share: |                    |           |            |            |
| Basic   | 28,020             | 9,352     | 18,195     | 3,730      |
| Diluted   | 28,581             | 9,352     | 18,195     | 3,730      |
| Pro forma net earnings (loss) per common share from continuing operations(b)  |                    |           |            |            |
| Basic   | \$ 0.29            | \$ (2.46) | \$ (4.78)  | \$ (1.60)  |
| Diluted   | \$ 0.29            | \$ (2.46) | \$ (4.78)  | \$ (1.60)  |
| Weighted-average common shares (in thousands), used in computing the pro forma net earnings per share:  |                    |           |            |            |
| Basic   | 28,020             | 21,321    | 25,583     | 22,331     |
| Diluted   | 28,581             | 21,321    | 25,583     | 22,331     |

(a) For the year ended November 30, 2004 benefit for income taxes includes a benefit of \$12,233,000 for the tax allowance of non-cash equity compensation. Of this benefit \$8,174,000 relates to the three months ended August 31, 2004. This benefit had not previously been recorded in press releases for the three months ended August 31, 2004. Accordingly, the net loss for the three and nine month periods ended August 31, 2004 amounted to \$166,305,000 and \$143,377,000 respectively compared to \$174,479,000 and \$151,551,000 as previously presented and basic and diluted loss per share for these periods amounted to \$7.37 and \$9.61 respectively compared to \$7.73 and \$10.16 as previously presented. (Basic and diluted loss per share from continuing operations in those periods amounted to \$6.80 and \$8.74 compared to \$7.16 and \$9.29 as previously presented. Basic and diluted proforma net loss per share amounted to \$5.67 and \$5.26 compared to \$5.97 and \$5.59 as previously presented). There is no impact to non-GAAP net income and proforma basic and diluted earnings per share as this tax benefit is included in non-GAAP adjustments.

(b) Pro forma earnings per share reflects the conversion of Xyratex Group Limited class A and class B preferred ordinary shares and class C ordinary shares to common shares of Xyratex Ltd on completion of its initial public offering, on June 29, 2004.

**XYRATEX LTD**  
**UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS**

|   | <u>November 30,<br/>2004</u> | <u>November 30,<br/>2003</u> |
|---|------------------------------|------------------------------|
| (US dollars and amounts in thousands)   |                              |                              |
| <b>ASSETS</b>   |                              |                              |
| <b>Current assets:</b>  |                              |                              |
| Cash and cash equivalents   | \$ 63,495                    | \$ 2,008                     |
| Accounts receivable net of allowance for doubtful accounts of \$198 and \$371   | 49,656                       | 40,866                       |
| Inventories   | 43,014                       | 37,849                       |
| Prepaid expenses  | 2,594                        | 2,099                        |
| Deferred income taxes   | 6,774                        | 3,429                        |
| Other current assets  | 2,855                        | 5,294                        |
|   | <u>168,388</u>               | <u>91,545</u>                |
| <b>Total current assets</b>   | <b>168,388</b>               | <b>91,545</b>                |
| Property, plant and equipment, net  | 14,495                       | 10,403                       |
| Intangible assets, net  | 7,911                        |                              |
| Deferred income taxes   | 14,448                       | 9,323                        |
|   | <u>205,242</u>               | <u>111,271</u>               |
| <b>Total assets</b>   | <b>\$ 205,242</b>            | <b>\$ 111,271</b>            |
| <b>LIABILITIES AND SHAREHOLDERS' EQUITY</b>   |                              |                              |
| <b>Current liabilities:</b>   |                              |                              |
| Accounts payable  | \$ 47,067                    | \$ 40,465                    |
| Acquisition note payable  | 2,000                        |                              |
| Short-term borrowings   | 4,000                        | 4,133                        |
| Customer advance  |                              | 1,073                        |
| Employee compensation and benefits payable  | 10,811                       | 12,421                       |
| Deferred revenue  | 1,887                        | 9,810                        |
| Income taxes payable  | 462                          | 315                          |
| Deferred income taxes   | 536                          | 354                          |
| Other accrued liabilities   | 10,778                       | 8,699                        |
|   | <u>77,541</u>                | <u>77,270</u>                |
| <b>Total current liabilities</b>  | <b>77,541</b>                | <b>77,270</b>                |
| Long-term debt  | 11,000                       | 15,000                       |
|   | <u>88,541</u>                | <u>92,270</u>                |
| <b>Total liabilities</b>  | <b>88,541</b>                | <b>92,270</b>                |
| <b>Shareholders' equity</b>   |                              |                              |
| Common shares of Xyratex Ltd (in thousands), par value \$0.01 per share<br>70,000 authorized, 28,043 issued and outstanding | 280                          |                              |
| Ordinary Shares of Xyratex Group Limited (in thousands), par value £0.01 per<br>share:                                      |                              |                              |
| Class B preferred ordinary shares; 11,099 shares authorized, Nil and 11,099<br>shares issued and outstanding                |                              | 169                          |
| Class A preferred ordinary shares; 16,325 shares authorized, Nil and 8,845<br>shares issued and outstanding                 |                              | 133                          |
| Class C ordinary shares; 2,576 shares authorized, Nil and Nil shares issued<br>and outstanding                              |                              |                              |
| Additional paid-in capital  | 329,267                      | 95,025                       |
| Accumulated other comprehensive income  | 755                          | 2,106                        |
| Accumulated deficit   | (213,601)                    | (78,432)                     |
|   | <u>116,701</u>               | <u>19,001</u>                |
| <b>Total shareholders' equity</b>   | <b>116,701</b>               | <b>19,001</b>                |

Edgar Filing: XYRATEX LTD - Form 6-K

|   | November 30,<br>2004 | November 30,<br>2003 |
|---|----------------------|----------------------|
| <b>Total liabilities and shareholders' equity</b> | <b>\$ 205,242</b>    | <b>\$ 111,271</b>    |

---

**XYRATEX LTD**  
**UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

|  | Year Ended           |                      |
|--|----------------------|----------------------|
|  | November 30,<br>2004 | November 30,<br>2003 |

(US dollars in thousands)

(a)

|   |              |             |
|---|--------------|-------------|
| <b>Cash flows from operating activities:</b>  |              |             |
| Net loss from continuing operations   | \$ (122,245) | \$ (35,815) |
| Adjustments to reconcile net income (loss) from continuing operations to net cash used in operating activities: |              |             |
| Depreciation  | 5,336        | 4,969       |
| Amortization of intangible assets   | 1,169        |             |
| Non-cash equity compensation  | 168,149      | 57,261      |
| Bonus paid by trust   |              | 1,573       |
| In process research and development   | 852          |             |
| Private equity and restructuring costs  |              | 4,682       |
| Loss (gain) on sale of assets   | (36)         | 71          |
| Supplier note receivable  | (6,000)      |             |
| Changes in assets and liabilities, net of impact of acquisitions and divestitures                               |              |             |
| Accounts receivable   | (6,695)      | (7,820)     |
| Inventories   | (2,084)      | (9,832)     |
| Prepaid expenses and other current assets   | 244          | (947)       |
| Accounts payable  | 4,251        | 5,208       |
| Customer advance  | (1,073)      | (1,227)     |
| Employee compensation and benefits payable  | (1,610)      | 4,837       |
| Deferred revenue  | (11,093)     | 9,209       |
| Income taxes payable  | 147          | (1,479)     |
| Deferred income taxes   | (7,709)      | (13,538)    |
| Amount payable to related party   |              | (1,342)     |
| Other accrued liabilities   | 1,234        | 3,951       |
|   | 22,837       | 19,761      |
| <b>Cash flows from investing activities:</b>  |              |             |
| Investments in property, plant and equipment  | (8,985)      | (5,107)     |
| Dispositions of property, plant and equipment   | 36           |             |
| Disposal of business, net of cash disposed and costs of disposition   |              | (175)       |
| Acquisition of business, net of cash received   | (7,418)      |             |
| Repayment of supplier note receivable   | 6,000        |             |
|   | (10,367)     | (5,282)     |
| <b>Cash flows from financing activities:</b>  |              |             |
| Net payments of short-term borrowings   | (4,133)      | (4,630)     |
| Proceeds of long-term borrowings  |              | 19,000      |
| Payments of long-term borrowings  |              | (7,850)     |
| Repurchase of ordinary shares   |              | (18,939)    |
| Proceeds from issuance of Ordinary Shares   | 53,150       | 273         |
|   | 49,017       | (12,146)    |
| Net cash used in discontinued operations  |              | (780)       |

Edgar Filing: XYRATEX LTD - Form 6-K

|  | Year Ended |          |
|--|------------|----------|
| Change in cash and cash equivalents              | 61,487     | 1,553    |
| Cash and cash equivalents at beginning of period | 2,008      | 455      |
| Cash and cash equivalents at end of period       | \$ 63,495  | \$ 2,008 |

(a)

Certain balances have been reclassified to be consistent with the current year.

## XYRATEX LTD

## UNAUDITED RECONCILIATION OF GAAP NET INCOME FROM CONTINUING OPERATIONS TO NON-GAAP NET INCOME

|  | Three Months Ended           |                           |                                  |
|--|------------------------------|---------------------------|----------------------------------|
|  | GAAP<br>November 30,<br>2004 | Non-GAAP<br>Adjustment(a) | Non-GAAP<br>November 30,<br>2004 |
| (US dollars in thousands, except per share amounts)  |                              |                           |                                  |
| Revenues   | \$ 116,701                   |                           | \$ 116,701                       |
| Cost of revenues non cash equity compensation  | 36                           | (36)                      |                                  |
| Cost of revenues other   | 92,451                       |                           | 92,451                           |
| Total cost of revenues   | 92,487                       |                           | 92,451                           |
| Gross profit   | 24,214                       |                           | 24,250                           |
| Operating expenses:  |                              |                           |                                  |
| Research and development non cash equity compensation  | 83                           | (83)                      |                                  |
| Research and development other   | 10,597                       |                           | 10,597                           |
| Total research and development   | 10,680                       |                           | 10,597                           |
| Selling, general and administrative non cash equity compensation                                       | 478                          | (478)                     |                                  |
| Selling, general and administrative other  | 7,884                        |                           | 7,884                            |
| Total selling, general and administrative  | 8,362                        |                           | 7,884                            |
| Amortization of intangible assets  | 397                          | (397)                     |                                  |
| In process research and development  | 852                          | (852)                     |                                  |
| Other costs  | (201)                        | 201                       |                                  |
| Total operating expenses   | 20,090                       |                           | 18,481                           |
| Operating income   | 4,124                        |                           | 5,769                            |
| Interest income (expense), net   | 147                          |                           | 147                              |
| Income from continuing operations before income taxes  | 4,271                        |                           | 5,916                            |
| Provision (benefit) for income taxes   | (3,937)                      | 4,409                     | 472                              |
| Net income from continuing operations  | \$ 8,208                     |                           | \$ 5,444                         |
| Pro forma net earnings (loss) per common share from continuing operations                              |                              |                           |                                  |
| Basic  | \$ 0.29                      |                           | \$ 0.19                          |
| Diluted  | \$ 0.29                      |                           | \$ 0.19                          |
| Weighted-average common shares (in thousands), used in computing the pro forma net earnings per share: |                              |                           |                                  |
| Basic  | 28,020                       |                           | 28,020                           |

Edgar Filing: XYRATEX LTD - Form 6-K

Three Months Ended

---

|         |        |        |
|---------|--------|--------|
|         | <hr/>  | <hr/>  |
|         | <hr/>  | <hr/>  |
| Diluted | 28,581 | 28,581 |
|         | <hr/>  | <hr/>  |

---

## XYRATEX LTD

## UNAUDITED RECONCILIATION OF GAAP NET INCOME FROM CONTINUING OPERATIONS TO NON-GAAP NET INCOME

|  | Year Ended                   |                           |                                  |
|--|------------------------------|---------------------------|----------------------------------|
|  | GAAP<br>November 30,<br>2004 | Non-GAAP<br>Adjustment(a) | Non-GAAP<br>November 30,<br>2004 |
| (US dollars in thousands, except per share amounts)                          |                              |                           |                                  |
| Revenues   | \$ 459,014                   |                           | \$ 459,014                       |
| Cost of revenues non cash equity compensation                                | 7,827                        | (7,827)                   |                                  |
| Cost of revenues other   | 356,558                      |                           | 356,558                          |
| Total cost of revenues   | 364,385                      |                           | 356,558                          |
| Gross profit   | 94,629                       |                           | 102,456                          |
| Operating expenses:  |                              |                           |                                  |
| Research and development development arrangement                             | (6,000)                      | 6,000                     |                                  |
| Research and development non cash equity compensation                        | 23,959                       | (23,959)                  |                                  |
| Research and development other   | 37,429                       |                           | 37,429                           |
| Total research and development   | 55,388                       |                           | 37,429                           |
| Selling, general and administrative non cash equity compensation             | 136,363                      | (136,363)                 |                                  |
| Selling, general and administrative other                                    | 28,005                       |                           | 28,005                           |
| Total selling, general and administrative                                    | 164,368                      |                           | 28,005                           |
| Amortization of intangible assets  | 1,169                        | (1,169)                   |                                  |
| In process research and development  | 852                          | (852)                     |                                  |
| Other costs  | 2,388                        | (2,388)                   |                                  |
| Total operating expenses   | 224,165                      |                           | 65,434                           |
| Operating income (loss)  | (129,536)                    |                           | 37,022                           |
| Interest income (expense), net   | 1,052                        | (933)                     | 119                              |
| Income (loss) from continuing operations before income taxes                 | (128,484)                    |                           | 37,141                           |
| Provision (benefit) for income taxes   | (6,239)                      | 12,534                    | 6,295                            |
| Net income (loss) from continuing operations                                 | \$ (122,245)                 |                           | \$ 30,846                        |
| Pro forma net earnings (loss) per common share from continuing operations(b) |                              |                           |                                  |
| Basic  | \$ (4.78)                    |                           | \$ 1.21                          |
| Diluted  | \$ (4.78)                    |                           | \$ 1.18                          |

Weighted-average common shares (in thousands), used in computing the pro forma net earnings per share:

Edgar Filing: XYRATEX LTD - Form 6-K

|         | Year Ended |        |
|---------|------------|--------|
| Basic   | 25,583     | 25,583 |
| Diluted | 25,583     | 26,225 |

## XYRATEX LTD

## UNAUDITED RECONCILIATION OF GAAP NET INCOME FROM CONTINUING OPERATIONS TO NON-GAAP NET INCOME

|  | Three Months Ended           |                           |                                  |
|--|------------------------------|---------------------------|----------------------------------|
|  | GAAP<br>November 30,<br>2003 | Non-GAAP<br>Adjustment(a) | Non-GAAP<br>November 30,<br>2003 |
| (US dollars in thousands, except per share amounts)  |                              |                           |                                  |
| Revenues   | \$ 99,363                    |                           | \$ 99,363                        |
| Cost of revenues non cash equity compensation  | 690                          | (690)                     |                                  |
| Cost of revenues other   | 77,242                       |                           | 77,242                           |
| Total cost of revenues   | 77,932                       |                           | 77,242                           |
| Gross profit   | 21,431                       |                           | 22,121                           |
| Operating expenses:  |                              |                           |                                  |
| Research and development non cash equity compensation  | 2,428                        | (2,428)                   |                                  |
| Research and development other   | 10,529                       |                           | 10,529                           |
| Total research and development   | 12,957                       |                           | 10,529                           |
| Selling, general and administrative non cash equity compensation                                       | 54,143                       | (54,143)                  |                                  |
| Selling, general and administrative other  | 8,210                        |                           | 8,210                            |
| Total selling, general and administrative  | 62,353                       |                           | 8,210                            |
| Other costs  | 11,625                       | (11,625)                  |                                  |
| Total operating expenses   | 86,935                       |                           | 18,739                           |
| Operating income (loss)  | (65,504)                     |                           | 3,382                            |
| Interest income (expense), net   | (15)                         |                           | (15)                             |
| Income (loss) from continuing operations before income taxes   | (65,519)                     |                           | 3,367                            |
| Provision (benefit) for income taxes   | (13,047)                     | 12,752                    | (295)                            |
| Net income (loss) from continuing operations   | \$ (52,472)                  |                           | \$ 3,662                         |
| Pro forma net earnings (loss) per common share from continuing operations                              |                              |                           |                                  |
| Basic  | \$ (2.46)                    |                           | \$ 0.17                          |
| Diluted  | \$ (2.46)                    |                           | \$ 0.17                          |
| Weighted-average common shares (in thousands), used in computing the pro forma net earnings per share: |                              |                           |                                  |
| Basic  | 21,321                       |                           | 21,321                           |
| Diluted  | 21,321                       |                           | 21,793                           |

Three Months Ended

---

---

---

---

## XYRATEX LTD

## UNAUDITED RECONCILIATION OF GAAP NET INCOME FROM CONTINUING OPERATIONS TO NON-GAAP NET INCOME

|  | Year Ended                   |                           |                                  |
|--|------------------------------|---------------------------|----------------------------------|
|  | GAAP<br>November 30,<br>2003 | Non-GAAP<br>Adjustment(a) | Non-GAAP<br>November 30,<br>2003 |
| (US dollars in thousands, except per share amounts)  |                              |                           |                                  |
| Revenues   | \$ 333,769                   |                           | \$ 333,769                       |
| Cost of revenues non cash equity compensation  | 690                          | (690)                     |                                  |
| Cost of revenues other   | 260,020                      |                           | 260,020                          |
| Total cost of revenues   | 260,710                      |                           | 260,020                          |
| Gross profit   | 73,059                       |                           | 73,749                           |
| Operating expenses:  |                              |                           |                                  |
| Research and development non cash equity compensation  | 2,428                        | (2,428)                   |                                  |
| Research and development other   | 29,797                       |                           | 29,797                           |
| Total research and development   | 32,225                       |                           | 29,797                           |
| Selling, general and administrative non cash equity compensation                                       | 54,143                       | (54,143)                  |                                  |
| Selling, general and administrative other  | 22,426                       |                           | 22,426                           |
| Total selling, general and administrative  | 76,569                       |                           | 22,426                           |
| Other costs  | 11,625                       | (11,625)                  |                                  |
| Total operating expenses   | 120,419                      |                           | 52,223                           |
| Operating income (loss)  | (47,360)                     |                           | 21,526                           |
| Interest income (expense), net   | (209)                        |                           | (209)                            |
| Income (loss) from continuing operations before income taxes   | (47,569)                     |                           | 21,317                           |
| Provision (benefit) for income taxes   | (11,754)                     | 12,752                    | 998                              |
| Net income (loss) from continuing operations   | \$ (35,815)                  |                           | \$ 20,319                        |
| Pro forma net earnings (loss) per common share from continuing operations(b)                           |                              |                           |                                  |
| Basic  | \$ (1.60)                    |                           | \$ 0.91                          |
| Diluted  | \$ (1.60)                    |                           | \$ 0.90                          |
| Weighted-average common shares (in thousands), used in computing the pro forma net earnings per share: |                              |                           |                                  |
| Basic  | 22,331                       |                           | 22,331                           |
| Diluted  | 22,331                       |                           | 22,821                           |

Year Ended

---

---

---

(a)

Non-GAAP Adjustment for the three and twelve month periods ended November 30, 2004 includes non-cash equity compensation expense, non-cash amortization of intangible assets, in process research and development expense, the related tax effects and expenses recorded in connection with our preparation for the initial public offering. Non-GAAP Adjustment for the twelve months ended November 30, 2004 also includes the elimination of the bad debt allowance on a supplier loan of \$6,000,000 and accrued interest of \$933,000 together with the related tax on the accrued interest. Non-GAAP Adjustment for the three and twelve month periods ended November 30, 2003 includes non-cash equity compensation expense, the release of the deferred tax valuation allowance relating primarily to UK loss carryforwards and expenses recorded in connection with the investment by HgCapital, a European private equity firm.

---

## Edgar Filing: XYRATEX LTD - Form 6-K

We believe these Non-GAAP measures are useful to investors because they provide an alternative method of measuring the operating performance of our business by excluding certain expenses, gains and losses which we believe are not indicative of our core operating results.

(b)

Pro forma earnings per share reflects the conversion of Xyratex Group Limited class A and class B preferred ordinary shares and class C ordinary shares to common shares of Xyratex Ltd on completion of its initial public offering, on June 29, 2004.

---

QuickLinks

SIGNATURES

XYRATEX LTD UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

XYRATEX LTD UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

XYRATEX LTD UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

XYRATEX LTD UNAUDITED RECONCILIATION OF GAAP NET INCOME FROM CONTINUING OPERATIONS TO NON-GAAP NET INCOME

XYRATEX LTD UNAUDITED RECONCILIATION OF GAAP NET INCOME FROM CONTINUING OPERATIONS TO NON-GAAP NET INCOME

XYRATEX LTD UNAUDITED RECONCILIATION OF GAAP NET INCOME FROM CONTINUING OPERATIONS TO NON-GAAP NET INCOME

XYRATEX LTD UNAUDITED RECONCILIATION OF GAAP NET INCOME FROM CONTINUING OPERATIONS TO NON-GAAP NET INCOME